Is Personalized Medicine a Solution for the Antibiotic Crisis?
Conference Recording Jun 01, 2013
About the Speaker
Till is Chief Operating Officer (COO) and Head of Biochip Research of the Division of Pathway Medicine at the University of Edinburgh. He has a PhD (summa cum laude) in biosensors from the University of Stuttgart and research at the University of Tokyo, as well as a German Habilitation in Analytical Biotechnology.
Antibiotic resistance is a major challenge for the modern healthcare system and increases the global burden of infectious diseases. The wrong use of antibiotics led to a situation of vanishing efficacy rates for antibiotic treatments due to the presence of resistant pathogens. To make things worse, the pipeline for new antibiotics is almost dry. Diagnostics could help reduce this threat but current standard methods are too slow and lack information depth to enable tailored therapy decisions. To overcome this limitation molecular tools are developed for rapid in vitro diagnostics of infectious diseases. In an ideal scenario such devices would be available at point of care to make therapy decisions at the site of the patient possible. In light of the current technology landscape the presentation will describe our developments on DNA microarrays and homogeneous multiplexing assays for rapid genotyping of antibiotic resistances of bacterial pathogens (e.g. ESBL and carbapenemases) or electrochemical biosensors for point of care detection of major pathogens (e.g. MRSA and Carbapenem-Resistant Enterobacteriaceae (CRE)). The combination of such diagnostic tests with their linked antibiotic therapy will enable a more stratified approach to antibiotic therapy. Consideration will be given in the presentation on how such strategies could be implemented in the patient pathway.